Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA study group

Journal of Infectious Diseases

Volumn 190, Issue 11, 2004, Pages 1947-1956

  Mocroft, A ^a   Ledergerber, B ^c   Viard, J P ^d   Staszewski, S ^e   Murphy, M ^b   Chiesi, A ^f   Horban, A ^g   Hansen, A B E ^h   Phillips, A N ^a   Lundgren, J D ⁱ  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^h Rigshospitalet   (Denmark)

ⁱ HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CONFIDENCE INTERVALS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; PREVALENCE; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 9444228307     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/425424     Document Type: Article

References (44)

1. BHIVA writing committee. British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 2:276-313.
2. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA panel. JAMA 2002; 288:222-35.
3. + T cell response after virological failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 131:946-53.
4. Mocroft A, Phillips AN, Miller V, et al. The use and response to secondline protease inhibitor regimens: results from the EuroSIDA study. AIDS 2001; 15:201-9.
5. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-43.
6. Tebas P, Patick AK, Kane EM, et al. Virological responses to a ritonavirsaquinavir containing regimen in patients who had previously failed nelfinavir. AIDS 1999; 13:F23-8.
7. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004:364:51-62.
8. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viraemia. AIDS 2002; 16:201-7.
9. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-33.
10. Lazzarin A, Clotet B, Cooper DA, et al. Efficacy of enfurvitude in patients infected with drug resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.
11. Benson CA, Decks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002; 185:599-607.
12. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-9.
13. World Health Organization. Treatment urgently needed for millions of people living with HIV/AIDS (press release 17 September 2003). Available at: http://www.who.int/mediacentre/news/notes/2003/ma11/en/. Accessed 26 October 2004.
14. Gullick RM, Mellors JW, Havlir D, E et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133:35-9.
15. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14:959-69.
16. Le Moing V, Chene G, Carrierri MP, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16:21-9.
17. Phillips AN, Staszewski S, Lampe F, et al. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002; 186:1086-91.
18. Palella FJ, Chmiel JS, Moorman AC, Holmberg SD, HIV Outpatients Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16:1617-26.
19. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy. Arch Intern Med 2000; 160:1123-32.
20. Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14:141-9.
21. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002; 185:178-87.
22. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-8.
23. Lee N, Hogg RS, Yip B, et al. Rates of disease progression among human immunodeficiency virus-infected persons initiating multipledrug rescue therapy. J Infect Dis 2003; 188:137-41.
24. Ammaranond P, Cunningham P, Oelrichs R, et al. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J Clin Virol 2003; 26: 153-61.
25. Tashima KT, Carpenter CCJ. Fusion inhibition-a major but costly step forward in the treatment of HIV-1 [editorial]. N Engl J Med 2003; 348:2249-50.
26. Carpenter CCJ, Fischl MA, Hammer SN, et al. Antiretroviral therapy for HIV in 1996: recommendations of an international panel. JAMA 1996; 276:146-54.
27. Hall CS, Raines CP, Barnett SH, Moore RD, Gallant JE. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS 1999; 13:1207-12.
28. Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11:F113-6.
29. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999; 13:F71-7.
30. Staszewski S, Miller V, Sabin CA, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999; 13:367-73.
31. Khanna N, Klimkait T, Schiffer V, et al. Salvage therapy with abacavir plus non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. AIDS 2000; 14: 791-9.
32. Decks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virological outcome. J Infect Dis 1999; 179:1375-81.
33. Durant J, Clevenbergh P, Halfon P, et al. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-9.
34. Friis-Moller N, Sabin CA, Weber R, et al., for the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003 [erratum: N Engl J Med 2004; 350:955].
35. Friis-Moller N, Sabin CA, Weber R, et al., for the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003 [erratum: N Engl J Med 2004; 350:955].
36. Nieuwkerk PT, Sprangers MAG, Burger DM, et al. Limited patients adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001; 161:1962-8.
37. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort study. Lancet 2001; 358:1322-7.
38. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virological failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
39. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virological failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000; 283:205-11.
40. Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral experienced patients. AIDS 2001; 15:2385-95.
41. Miller V, Cozzi-Lepri A, Hertogs K, et al. HIV drug susceptibility and treatment response to mega-HAART regimens in patients from the Frankfurt HIV cohort. Antivir Ther 2000; 5:49-55.
42. Fischl MA, Ribaudo HJ, Collier AC, et al. A randomised trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003; 188:625-34.
43. Phillips AN, Youle MS, Lampe F, et al. Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. AIDS 2003; 17:1009-16.
44. Lazzarin A, Clotet B, Cooper DA, et al. Efficacy of enfurvitude in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.